Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 38,800 shares, a growth of 9.6% from the September 15th total of 35,400 shares. Based on an average trading volume of 39,300 shares, the short-interest ratio is currently 1.0 days. Currently, 0.5% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research note on Wednesday, August 14th.
Get Our Latest Stock Report on Daré Bioscience
Daré Bioscience Stock Up 0.6 %
Daré Bioscience (NASDAQ:DARE – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $2.09. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million. As a group, equities analysts forecast that Daré Bioscience will post -0.27 EPS for the current fiscal year.
Institutional Investors Weigh In On Daré Bioscience
A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its position in Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by institutional investors and hedge funds.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Ride Out The Recession With These Dividend Kings
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- The Role Economic Reports Play in a Successful Investment Strategy
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.